Sulfadoxine-pyrimethamine plus chloroquine or amodiaquine for uncomplicated falciparum malaria: A randomized, multisite trial to guide national policy in Uganda

American Journal of Tropical Medicine and Hygiene

Volumn 72, Issue 5, 2005, Pages 573-580

  Bakyaita, Nathan ^a   Dorsey, Grant ^b   Yeka, Adoke ^a   Banek, Kristin ^b   Staedke, Sarah G ^b   Kamya, Moses R ^c   Talisuna, Ambrose ^a   Kironde, Fred ^c   Nsobya, Sam ^c   Kilian, Albert ^a   Reingold, Arthur ^d   Rosenthal, Philip J ^b   Wabwire Mangen, Fred ^e  

^a MINISTRY OF HEALTH   (Uganda)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAKERERE UNIVERSITY MEDICAL SCHOOL   (Uganda)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e MAKERERE UNIVERSITY SCHOOL OF PUBLIC HEALTH   (Uganda)

Author keywords

[No Author keywords available]

Indexed keywords

AMODIAQUINE; ANTIMALARIAL AGENT; CHLOROQUINE; COSMOQUINE; FANSIDAR; HEMOGLOBIN; PYRIMETHAMINE; SULFADOXINE; SULFADOXINE-PYRIMETHAMINE;

ALLELE; ARTICLE; BLOOD SMEAR; CLINICAL TRIAL; COMMON COLD; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEVER; FOLLOW UP; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALARIA; MULTICENTER STUDY; PLASMODIUM FALCIPARUM; POLICY; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; UGANDA; CHILD; COMPARATIVE STUDY; DRUG COMBINATION; HEALTH CARE POLICY; INFANT; MALARIA FALCIPARUM; PRESCHOOL CHILD;

AMODIAQUINE; ANTIMALARIALS; CHILD; CHILD, PRESCHOOL; CHLOROQUINE; DRUG COMBINATIONS; DRUG THERAPY, COMBINATION; HEALTH POLICY; HUMANS; INFANT; MALARIA, FALCIPARUM; PYRIMETHAMINE; SULFADOXINE; UGANDA;

EID: 20544476722     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.2005.72.573     Document Type: Article

References (16)

1. World Health Organization, Position of WHO'S Roll Back Malaria Department on malaria treatment policy, http:// www.emro.who.int/rbm.
2. Korenromp EL, Williams BG, Gouws E, Dye C, Snow RW, 2003. Measurement of trends in childhood malaria mortality in Africa: an assessment of progress toward targets based on verbal autopsy. Lancet Infect Dis 3: 349-358.
3. Trape JF, 2001. The public health impact of chloroquine resistance in Africa. Am J Trop Med Hyg 64: 12-17.
4. Dorsey G, Njama D, Kamya MR, Cattamanchi A, Kyabayinze D, Staedke SG, Gasasira A, Rosenthal PJ, 2002. Sulfadoxine/pyrimethamine alone or with amodiaquine or artesunate for treatment of uncomplicated malaria: a longitudinal randomised trial. Lancet 360: 2031-2038.
5. Gasasira AF, Dorsey G, Nzarubara B, Staedke SG, Nassau A, Rosenthal PJ, Kamya MR, 2003. Comparative efficacy of aminoquinoline-antifolate combinations for the treatment of uncomplicated falciparum malaria in Kampala, Uganda. Am J Trop Med Hyg 68: 127-132.
6. Staedke SG, Kamya MR, Dorsey G, Gasasira A, Ndeezi G, Charlebois ED, Rosenthal PJ, 2001. Amodiaquine, sulfadoxine/pyrimethamine, and combination therapy for treatment of uncomplicated falciparum malaria in Kampala, Uganda: a randomised trial. Lancet 358: 368-374.
7. Attaran A, Barnes KI, Curtis C, d'Alessandro U, Fanello CI, Galinski MR, Kokwaro G, Looareesuwan S, Makanga M, Mutabingwa TK, Talisuna A, Francois Trape J, Watkins WM, 2004. WHO, the Global Fund, and medical malpractice in malaria treatment. Lancet 363: 237-240.
8. Kamya MR, Bakyaita NN, Talisuna AO, Were WM, Staedke SG, 2002. Increasing antimalarial drug resistance in Uganda and revision of the national drug policy. Trop Med Int Health 7: 1031-1041.
9. Monitoring antimalarial drug resistance within National Malaria Control Programmes: the EANMAT experience. Trop Med Int Health 6: 891-898.
10. World Health Organization, 2003. Assessment and monitoring of antimalarial drug efficacy for the treatment of uncomplicated falciparum malaria. Geneva: World Health Organization technical document. WHO/HTM/RBM/2003.50.
11. World Health Organization, 1996. Assessment of therapeutic efficacy of antimalarial drugs for uncomplicated falciparum malaria in areas with intense transmission. Geneva: World Health Organization technical document. WHO/MAL/96.1077.
12. Cattamanchi A, Kyabayinze D, Hubbard A, Rosenthal PJ, Dorsey G, 2003. Distinguishing recrudescence from reinfection in a longitudinal antimalarial drug efficacy study: comparison of results based on genotyping of msp-1, msp-2, and glurp. Am J Trop Med Hyg 68: 133-139.
13. White N, 2002. The assessment of antimalarial drug efficacy. Trends Parasitol 18: 458-464.
14. Phillips-Howard PA, West LJ, 1990. Serious adverse drug reactions to pyrimethamine-sulphadoxine, pyrimethaminedapsone and to amodiaquine in Britain. J R Soc Med 83:82-85.
15. Snow RW, Eckert E, Teklehaimanot A, 2003. Estimating the needs for artesunate-based combination therapy for malaria case-management in Africa. Trends Parasitol 19: 363-369.
16. Rwagacondo CE, Niyitegeka F, Sarushi J, Karema C, Mugisha V, Dujardin JC, Van Overmeir C, van den Ende J, D'Alessandro U, 2003. Efficacy of amodiaquine alone and combined with sulfadoxine-pyrimethamine and of sulfadoxine pyrimethamine combined with artesunate. Am J Trop Med Hyg 68: 743-747.